BioSpace News Archive

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that it will host its virtual Vaccines Day for analysts and investors at 8:00 a.m. ET on Thursday, March 24.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the U.S. Food and Drug Administration (FDA) has set a date of April 22, 2022 for the previously announced meeting of the Oncologic Drugs Advisory Committee (ODAC) in connection with its review of the Biologics License Application (BLA)/supplemental New Drug Application.

Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, today reported positive clinical data from its recently completed Phase 1 clinical trial evaluating the safety and tolerability of PIPE-307 in healthy volunteers.

PAVmed Inc., a diversified commercial-stage medical technology company announced that its majority-owned digital health subsidiary Veris Health has launched a world-class technology advisory board consisting of Silicon Valley luminaries with broad expertise in software development, hardware engineering, data and analytics, machine learning, and consumer engagement.

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions, announced today that the Company’s CEO Dr. David Young, will present at the Oppenheimer 32nd Annual Healthcare Conference.

AquaBounty Technologies, Inc. (Nasdaq: AQB) (“AquaBounty” or the “Company”), a land-based aquaculture company utilizing technology to enhance productivity and sustainability, today announced the Company’s financial results for the fourth quarter and full year ended December 31, 2021.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to ALLO-316, the Company’s first AlloCAR T solid tumor clinical candidate for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC).

Mustang Bio, Inc. announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in March 2022.

Evoke Pharma, Inc., a specialty pharmaceutical company focused primarily on treatments for gastrointestinal diseases, announced that together with the research team at H.C. Wainwright & Co., it will host a virtual key opinion leader fireside chat on March 16, 2022, at 10:00 a.m. ET.

Nuvectis Pharma, Inc. (NASDAQ: NVCT), (“Nuvectis” or the “Company”) a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today announced that an abstract related to NXP800 has been selected for an oral presentation and an abstract related to NXP900 has been selected for a poster presentation at the upcoming 2022 American Association for Cancer Research Meeting.